---
search:
  boost: 2 
---

# Benign Prostatic Hyperplasia

This is a subcategory of Genitourinary Agents.

## Decision Tree

- [Benign Prostatic Hyperplasia- Non-Preferred - Cardura XL, Silodosin](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNDhQUkMyNUdBTVNBN0FGUkhYMURDR1UyQSQlQCN0PWcu&topview=Preview){ :target="_blank" rel="noopener"}
- [Benign Prostatic Hyperplasia- Non-Preferred- Dutasteride/Tamsulosin](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUQklRWUMzMFFFQkM4VzE4Q1hBSzlZU1NDWCQlQCN0PWcu&topview=Preview){ :target="_blank" rel="noopener"}
- [Benign Prostatic Hyperplasia - Tadalafil 2.5mg, 5mg](https://forms.office.com.mcas.ms/pages/designpagev2.aspx?auth_pvr=OrgId&auth_upn=anttwaniqua.greer%40gainwelltechnologies.com&origin=OfficeDotCom&lang=en-US&sessionid=dba554c2-2c78-4f60-bee3-f837172c2546&route=GroupForms&subpage=design&id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUNUs2SzRXTU9MTVhSVjc4NDdPNVRYQUJCNiQlQCN0PWcu&topview=Preview){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                         | Generic Name | Quantity | Time (Days) |
|:----------------------------------|:-------------|:--------:|:-----------:|
| Alfuzosin                         |              |          |             |
| Doxazosin                         |              |          |             |
| Dutasteride                       |              |          |             |
| Finasteride                       |              |          |             |
| Prazosin                          |              |          |             |
| Tadalafil <sup>PA</sup> 2.5, 5 MG |              |          |             |
| Tamsulosin                        |              |          |             |
| Terazosin                         |              |          |             |

### Non-Preferred

| Non-Preferred            | Generic Name | Quantity | Time (Days) |
|:-------------------------|:-------------|:--------:|:-----------:|
| Cardura XL               |              |          |             |
| Dutasteride / Tamsulosin |              |          |             |
| Entadfi                  |              |          |             |
| Silodosin                |              |          |             |

## Authorizations

**Length of Authorizations**: 365 Days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Tadalafil (Cialis)

Tadalafil (Cialis) Criteria

- Must have had an inadequate clinical response of at least **30 days** with at least **one** alpha-1 adrenergic blocker and at least **90 days** of finasteride

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **30 days** with at least **two preferred** drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Dutasteride / Tamsulosin (Jalyn) & Finasteride / Tadalafil (Entadfi)

Additional Dutasteride / Tamsulosin (Jalyn) & Finasteride / Tadalafil (Entadfi) Criteria

- Must provide documentation for patientâ€™s inability to use the individual drugs

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_Criteria%20_APPROVED.pdf#page=71){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230401_UPDL_v7_Approved.pdf#page=24){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
